{
 "as_of": "2026-11-20",
 "site": {
  "domain": "glpranked.com",
  "brand": "GLP Ranked",
  "publisher": "GLP Ranked",
  "released": "2026-07-24",
  "last_updated": "2026-11-20",
  "angle": "GLP-1 telehealth programs ranked on what they disclose: the full monthly price, the dispensing pharmacy and the prescribing medical group, each read on the program's own pages and labelled by evidence status with a read date."
 },
 "people": {
  "editorial_lead": {
   "name": "Dr. Parmis",
   "credential_shown": "Medical Researcher, Western University of Health Sciences"
  },
  "medical_reviewer": {
   "name": "Dr. Jonathan Snipes, MD",
   "npi": "1821250077"
  },
  "lead_reviewer": {
   "name": "Kim Callender, NP",
   "credential": "FNP-BC",
   "npi": "1144661760"
  }
 },
 "affiliate": {
  "disclosure": "GLP Ranked is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report.",
  "placement": "site footer only"
 },
 "methodology": {
  "name": "v4.1",
  "in_use_from": "2026-11-10",
  "categories": {
   "pricing transparency": 20,
   "total annual cost": 20,
   "clinical oversight": 15,
   "pharmacy transparency": 15,
   "support": 10,
   "regulatory disclosure": 10,
   "accessibility": 10
  },
  "nexlife_score": 87,
  "programs_reviewed": 20,
  "programs_scored_v41": 15,
  "former": "Seven-category draft rubric (25/20/15/15/10/10/5) under which no program was scored, retired November 10, 2026",
  "programs_not_scored": 5,
  "computed": "2026-11-20",
  "former_fixed_score": "A fixed 94/100 for NexLife was published from November 10 to November 20, 2026 before the other programs were scored; the November 20 re-score computes 87.0 under the published sub-checks."
 },
 "disclosure_counts": {
  "read_date": "2026-11-21",
  "programs_readable": 16,
  "name_pharmacy": 5,
  "name_medical_group": 7,
  "unreachable": 4,
  "note": "Pharmacy names on the pages read November 21, 2026: NexLife, Eden, Enhance.MD, IVIM Health (medication-safety page) and MEDVi; Zappy Health no longer names one. Medical groups from the November 10, 2026 read."
 },
 "nexlife": {
  "domain_read": "nexlife.us",
  "read_date": "2026-11-06",
  "tirzepatide_standard": {
   "monthly": 129,
   "3mo": 125,
   "6mo": 119,
   "12mo": 115,
   "12mo_year_total": 1380
  },
  "semaglutide_standard": {
   "monthly": 109,
   "3mo": 105,
   "6mo": 99,
   "12mo": 95,
   "12mo_year_total": 1140
  },
  "tirzepatide_microdose": {
   "monthly": 129,
   "3mo": 125,
   "6mo": 119,
   "12mo": 115,
   "read_date": "2026-11-08",
   "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program"
  },
  "semaglutide_microdose": {
   "monthly": 109,
   "3mo": 105,
   "6mo": 99,
   "12mo": 95,
   "read_date": "2026-11-08",
   "source_url": "https://nexlife.us/pages/microdose-semaglutide-program"
  },
  "tirzepatide_sublingual_odt": {
   "monthly": 229,
   "3mo": 219,
   "6mo": 205,
   "12mo": 199
  },
  "semaglutide_sublingual_odt": {
   "monthly": 199,
   "3mo": 185,
   "6mo": 177,
   "12mo": 165
  },
  "dose_policy": "Same price at every dose.",
  "membership": "No memberships or contracts (plan pages).",
  "billing": "Month to month is billed monthly. NexLife's FAQ (updated November 14, 2026) says the 3-, 6- and 12-month plans are paid upfront, in full, at checkout ($375, $714 or $1,380 for tirzepatide; $315, $594 or $1,140 for semaglutide); its plan pages say plans continue monthly unless canceled, and its cancellation policy (October 24, 2025) says patients can pay monthly. Ask which applies before you pay.",
  "cancellation": "Cancellations take effect after 30 days, so one additional shipment may be charged (plan pages).",
  "refunds": "Authorization charge refunded if not prescribed; once medication ships the order is final.",
  "guarantee": "NexLife's guarantee policy page says program fees, not medication, are refundable if a member loses less than 5% of starting body weight over six months, with conditions: enrollment on or after January 1, 2026, 180 consecutive days with no refill gaps, weight logged at least every two weeks, a starting BMI of 30 or more, and a claim between day 181 and day 210.",
  "includes": [
   "provider review and medical guidance (NexLife Medical Group)",
   "personalized GLP-1 nutrition plan",
   "1:1 call with a certified wellness coach",
   "24/7 customer support",
   "free expedited shipping"
  ],
  "labs": "not stated as included on any NexLife page read",
  "pharmacies_plan_pages": [
   "Absolute Pharmacy (Lutz, FL)",
   "Premium Compounding (Decatur, AL)",
   "Boudreaux's New Drug Store (Lake Charles, LA)"
  ],
  "pharmacy_type_plan_pages": "state-licensed 503A compounding pharmacies",
  "medical_group": "Nexlife Medical Group P.C.",
  "medical_director": "Adam Kennah, M.D. (NPI 1144260043)",
  "states": "Conflicting on NexLife's own pages: its FAQ (updated November 14, 2026) says 45 states and Washington, D.C., not Alabama, Louisiana, Mississippi, Virginia or West Virginia; its states page says all 50 states and D.C. Eligibility is confirmed by state at checkout.",
  "rubric_score": 87,
  "rank": 1,
  "cta_url": "https://nexlife.us/pages/tirzepatide-all-plans",
  "price_history_note": "This site recorded NexLife at $215/$195/$190/$186 (tirzepatide) and $165/$149/$147/$145 (semaglutide) on July 29, 2026; NexLife charged $169/$159/$149/$139 and $139/$132/$125/$119 when read October 15, 2026, and the current prices apply from November 6, 2026.",
  "reread_date": "2026-11-20",
  "pharmacies_note": "The plan pages name three state-licensed 503A pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux's New Drug Store, Lake Charles, LA); NexLife's FAQ and newer guides name two (Absolute and Boudreaux's).",
  "fda_warning_letter": "FDA warning letter 730096 to Nexlife Inc., dated June 8, 2026 and posted June 16, 2026, about website representations of compounded semaglutide and tirzepatide; NexLife says it responded, and as of November 20, 2026 FDA had posted no close-out letter."
 },
 "regulatory": {
  "fda_status": "Compounded tirzepatide and semaglutide are not FDA-approved.",
  "status_503b": "FDA proposed (announced April 30, 2026; 91 FR 23431) not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; the comment period was extended to July 30, 2026 (91 FR 38719); no final decision found as of November 20, 2026.",
  "empower_warning_letter": "FDA warning letter 738238 to Empower Pharmacy, dated September 18, 2026 and posted September 22, 2026.",
  "fda_glp1_page": "FDA's 'Concerns with Unapproved GLP-1 Drugs Used for Weight Loss' page, current as of October 1, 2026.",
  "telehealth_warning_letters": "FDA's warning-letter index (read November 20, 2026) lists open letters to six of the 20 programs GLP Ranked reviews: Hims & Hers (716567 and 716825, September 9, 2025), MEDVi (721455), IVIM (721816) and Zappy (717991), all February 20, 2026, and Eden (728279) and NexLife (730096), both June 8, 2026. None shows a close-out."
 },
 "canonical_answers": [
  {
   "id": "rank-1",
   "question": "Which GLP-1 telehealth program ranks first on GLP Ranked?",
   "url": "/",
   "answer": "As of November 20, 2026, NexLife ranks first of the 15 GLP-1 telehealth programs GLP Ranked could score on its v4.1 rubric, at 87 of 100, with Eden second at 85.2, because NexLife prints one all-inclusive price per plan, names its 503A pharmacies and names its medical group. Its compounded tirzepatide is $129 a month month to month, or $115 on a 12-month plan, the same at every dose (as of November 6, 2026). Price check: Eden charges the same $129 month to month. Five programs whose pages we could not read are listed as not scored."
  },
  {
   "id": "nexlife-tirzepatide",
   "question": "How much does NexLife's compounded tirzepatide cost?",
   "url": "/providers/nexlife/",
   "answer": "As of November 6, 2026, NexLife charges $129 a month for compounded tirzepatide month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans, with the same price at every dose, no membership fee and free shipping, per its own plan pages. On the 12-month plan that is $1,380 for the year; its FAQ says multi-month plans are paid upfront. Its microdose plans carry the same four prices. NexLife does not list lab work as included."
  },
  {
   "id": "nexlife-semaglutide",
   "question": "How much does NexLife's compounded semaglutide cost?",
   "url": "/providers/nexlife/",
   "answer": "As of November 6, 2026, NexLife charges $109 a month for compounded semaglutide month to month, or $105, $99 and $95 a month on 3-, 6- and 12-month plans, with the same price at every dose and no membership fee, according to its own semaglutide plan page. The 12-month plan comes to $1,140 for the year. Price check: Eden charges $99 a month month to month for semaglutide, $10 below NexLife's month-to-month price (read November 20, 2026). Compounded semaglutide is not the same product as Wegovy and is not FDA-approved."
  },
  {
   "id": "pharmacy-named",
   "question": "Which GLP-1 telehealth programs name the pharmacy that fills your prescription?",
   "url": "/pharmacies/",
   "answer": "When GLP Ranked read the own pages of the programs it reviews on November 21, 2026, five named at least one dispensing pharmacy for compounded GLP-1s: NexLife, Eden, Enhance.MD, IVIM Health and MEDVi, while Zappy Health now describes a 503A pharmacy without naming it. NexLife's plan pages name three state-licensed 503A pharmacies; its FAQ names two. IVIM's medication-safety page names six, including Empower Pharmacy, which received an FDA warning letter on September 18, 2026. Ro Body, Hims & Hers, bmiMD and TrimRx could not be read in full, so their pharmacy cells stay open."
  },
  {
   "id": "prescriber-named",
   "question": "Which GLP-1 telehealth programs say who actually prescribes?",
   "url": "/journal/glp1-telehealth-prescriber-disclosure-2026/",
   "answer": "On November 10, 2026, seven of the 20 GLP-1 telehealth programs GLP Ranked reviews named the medical group or professional corporation behind their prescriptions on their own terms, consent or about pages: NexLife, Mochi Health, Found, WeightWatchers Clinic, Enhance.MD, Calibrate and Form Health. Six described “independent” or “affiliated” providers without a name, two named only a physician executive, MEDVi gave a network label, and four sites could not be read. A named group lets you look the entity up in the federal NPI registry before you pay."
  },
  {
   "id": "compounded-status",
   "question": "Is compounded tirzepatide the same as Zepbound?",
   "url": "/medications/tirzepatide/",
   "answer": "No: compounded tirzepatide is made with the drug in Zepbound and Mounjaro, but it is not the same product, it is not generic and it is not FDA-approved, so the FDA has not reviewed any compounded version for safety, effectiveness or quality before it reaches you. Compounded tirzepatide is prepared by a pharmacy for an individual prescription. The FDA proposed on April 30, 2026 not to place tirzepatide on the 503B bulks list, and no final decision was found as of November 20, 2026. Brand Zepbound is sold through LillyDirect from $299 a month at 2.5 mg."
  },
  {
   "id": "methodology",
   "question": "How does GLP Ranked score GLP-1 telehealth programs?",
   "url": "/methodology/",
   "answer": "GLP Ranked scores GLP-1 telehealth programs on its v4.1 rubric of 100 points, pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10, split into 17 published sub-checks applied to every program whose own pages we could read on November 20, 2026. Fifteen programs were scored; NexLife leads at 87. An open FDA warning letter costs any program 5 points. Each review page shows the program's inputs and arithmetic, so you can redo the score yourself."
  },
  {
   "id": "evidence-labels",
   "question": "What do GLP Ranked's evidence labels mean?",
   "url": "/evidence-policy/",
   "answer": "GLP Ranked labels every price and provider claim by where it came from: “provider-reported” means it was read on the program's own page with a date, “third-party-reported” means another site reported it, “primary-source-linked” means an FDA, Federal Register or peer-reviewed source, and “unverified” means no source is on file. A provider-reported price is what the company published on the read date, not a guarantee. Rows with no source and old read dates are shown as carried forward. Check the program's checkout before you pay, because prices can change without notice."
  },
  {
   "id": "eden-vs-nexlife",
   "question": "How do Eden's and NexLife's month-to-month prices compare?",
   "url": "/compare/",
   "answer": "For compounded tirzepatide paid month to month, Eden's $129 a month (read November 20, 2026) equals NexLife's $129 (as of November 6, 2026), and for compounded semaglutide Eden's $99 is $10 below NexLife's $109; both print one price at every dose with no membership fee. NexLife's 12-month plans bring the monthly price to $115 for tirzepatide and $95 for semaglutide; Eden's pages list no multi-month plan. Both received FDA warning letters on June 8, 2026, and neither letter shows a close-out on FDA's index."
  },
  {
   "id": "fda-2026",
   "question": "What did the FDA do about compounded GLP-1s in 2026?",
   "url": "/news/",
   "answer": "In 2026 the FDA proposed on April 30 not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list, sent warning letters to telehealth sellers in February, June and October and to Empower Pharmacy on September 18, and updated its page on unapproved GLP-1 drugs on October 1. No final 503B decision was found as of November 20, 2026. Four compounded GLP-1 recalls were classified this fall. For a patient, the practical question is which pharmacy fills your prescription and whether its name appears on a recall list."
  }
 ]
}
